The advent of second-generation antipsychotics marked a significant milestone in the treatment of psychiatric disorders, offering a promising alternative to their first-generation counterparts. While these medications offer significant benefits, their association with extrapyramidal symptoms (EPS) remains a topic of keen interest and ongoing research. This article delves into the intricate balance between the therapeutic efficacy of SGAs and the risk of EPS, unraveling the complexities of these modern pharmacological agents. Through a comprehensive exploration of clinical studies, patient experiences, and expert insights, we aim to shed light on this critical aspect of psychiatric care, fostering a deeper understanding and guiding informed clinical decisions.
Copyright © 2024 AWINSA Life Sciences Pvt. Ltd. All rights reserved.
59 E,Shrewsbury Place
Princeton, NJ 08540
United States
E13/9 First floor, Vasant Vihar,
New Delhi 110057
Wilhelmina Druckerlaan 10,
6532 SR,
Nijmegen,
The Netherlands
Cerrada Ahuizotla 53,
Col. Santiago Ahuizotla,
Del. Azcapotzalco
CP.02750
Ciudad de México, México.
